Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2721777 | 0.86 | CA1 (0.37) | CA2CA1CA7CA13 | |
| SCHEMBL9936351 | 0.85 | USP2 (0.33) | CA2CA1CA7CA13 | |
| SCHEMBL1345425 | 0.83 | CA1 (0.35) | CA2CA1CA7CA13 | |
| SCHEMBL28239207 | 0.81 | CA1 (0.33) | CA2CA1CA7CA13 | |
| SCHEMBL4245730 | 0.81 | F2 (0.33) | CA2CA1CA7CA13 | |
| SCHEMBL5536943 | 0.81 | CA1 (0.33) | CA2CA1CA7CA13ALDH1A1 | |
| SCHEMBL758883 | 0.77 | CA2 (0.41) | CA2CA1CA7CA13ALDH1A1 | |
| SCHEMBL160 | 0.77 | CA2 (0.41) | CA2CA1CA7CA13ALDH1A1 | |
| SCHEMBL758884 | 0.77 | CA2 (0.41) | CA2CA1CA7CA13ALDH1A1 | |
| SCHEMBL3361727 | 0.76 | CA1 (0.30) | CA2CA1CA7CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116730890-A | Optically active trifluoromethanesulfonyl peroxide derivative and preparation method thereof | 西湖大学 | 2023-09-12 | — | — | CN | claimed |
| US-4406825-A | FLUORINE-CONTAINING PEROXIDE | ALLIED CORPORATION (US) | 1983-09-27 | — | — | US | claimed |
| US-4269738-A | MODIFYING A SOLID POLYACETYLENE WITH A FLUORINE-CONTAINING PEROXIDE, E.G. BISFLUOROSULFURYL PEROXIDE, IN A SOLVENT AT LOW TEMPERATURES AND PRESSURES; METAL-LIKE; SEMICONDUCTORS | ALLIED CHEMICAL CORPORATION (US) | 1981-05-26 | — | — | US | claimed |
| CN-122079960-A | Alkynyl quinazoline compounds | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4013749-B1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-3868384-B1 | CYCLIC DINUCLEOTIDES AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2026-02-25 | — | — | EP | disclosed |
| US-20260049063-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12435063-B2 | Nitrogen containing heterocycles as CDK12 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-10-07 | — | — | US | disclosed |
| US-12435046-B2 | Alkynyl quinazoline compounds | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250205270-A1 | ANTIBODY-DRUG CONJUGATE PRECURSORS COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-06-26 | — | — | US | disclosed |
| CN-119390683-A | Alkynyl quinazoline compounds | 黑钻治疗公司 | 2025-02-07 | — | — | CN | disclosed |
| US-8309714-B2 | Process for producing laurolactam | UBE INDUSTRIES, LTD. (JP) | 2012-11-13 | — | — | US | disclosed |
| US-8163899-B2 | Process for producing laurolactam | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-2346869-A2 | 5-OXAZOLIDIN-2-ONE SUBSTITUTED 1,3,8-TRIAZASPIRO [4.5] DECAN-4-ONE DERIVATIVES USEFUL AS ORL-1 RECEPTOR MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2011-07-27 | — | — | EP | disclosed |
| US-20100267944-A1 | PROCESS FOR PRODUCING LAUROLACTAM | UBE INDUSTRIES, LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100076003-A1 | 5-OXAZOLIDIN-2-ONE SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL AS ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-03-25 | — | — | US | disclosed |
| WO-2010033451-A2 | 5-OXAZOLIDIN-2-ONE SUBSTITUTED 1,3,8-TRIAZASPIRO [4.5] DECAN-4-ONE DERIVATIVES USEFUL AS ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-03-25 | — | — | WO | disclosed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| US-4406825-A | FLUORINE-CONTAINING PEROXIDE | ALLIED CORPORATION (US) | 1983-09-27 | — | — | US | disclosed |
| US-4269738-A | MODIFYING A SOLID POLYACETYLENE WITH A FLUORINE-CONTAINING PEROXIDE, E.G. BISFLUOROSULFURYL PEROXIDE, IN A SOLVENT AT LOW TEMPERATURES AND PRESSURES; METAL-LIKE; SEMICONDUCTORS | ALLIED CHEMICAL CORPORATION (US) | 1981-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435046-B2 | Alkynyl quinazoline compounds | GLS, GLS2, MCL1 | CA2 2340/4885CA1 3977/4885CA7 3171/4885 |
| US-20250205270-A1 | ANTIBODY-DRUG CONJUGATE PRECURSORS COMPRISING A CYCLIC DINUCLEOTIDE | STING1, CGAS, TLR9 | CA2 3143/4885CA1 4398/4885CA7 2841/4885 |
| US-20100076003-A1 | 5-OXAZOLIDIN-2-ONE SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL AS ORL-1 RECEPTOR MODULATORS | OXER1, OGFRL1, ORMDL3 | CA2 3409/4885CA1 4380/4885CA7 4777/4885 |
| US-20080103123-A1 | New compounds | GPR119, GPR139, GPR180 | CA2 1045/4885CA1 2523/4885CA7 2189/4885 |
| US-12435063-B2 | Nitrogen containing heterocycles as CDK12 inhibitors | CDK1, CDK12, CDK15 | CA2 1739/4885CA1 3300/4885CA7 3435/4885 |
| US-20260049063-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, BCL6 | CA2 546/4885CA1 2432/4885CA7 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.